Get the Stockscreener App
0.7092
1.33%
0.0093
After Hours:
.72
0.0108
+1.52%
Ironwood Pharmaceuticals Inc stock is traded at $0.7092, with a volume of 1.99M.
It is up +1.33% in the last 24 hours and down -31.15% over the past month.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
See More
Previous Close:
$0.6999
Open:
$0.69
24h Volume:
1.99M
Relative Volume:
0.54
Market Cap:
$150.86M
Revenue:
$400.57M
Net Income/Loss:
$9.21M
P/E Ratio:
17.73
EPS:
0.04
Net Cash Flow:
$146.36M
1W Performance:
-23.93%
1M Performance:
-31.15%
6M Performance:
-85.70%
1Y Performance:
-89.48%
1-Day Range:
$0.69
$0.7486
1-Week Range:
$0.69
$0.9596
52-Week Range:
$0.591
$7.19
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
0.7092 | 150.86M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Pacer Advisors, Inc. Reduces Stake in Ironwood Pharmaceuticals Inc. - GuruFocus
Pacer Advisors, Inc. Expands Stake in Ironwood Pharmaceuticals Inc. - GuruFocus
Ironwood Pharma Stock Draws Retail Investor Ire With Big Q1 Miss And No Earnings Call - MSN
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates - TradingView
Ironwood: Q1 Earnings Snapshot - New Haven Register
Ironwood at The Citizens JMP Life Sciences Conference: Strategic Outlook By Investing.com - Investing.com India
Ironwood at The Citizens JMP Life Sciences Conference: Strategic Outlook - Investing.com
Ironwood Pharmaceuticals (IRWD) Maintains LINZESS Sales Outlook Amid Pricing Challenges | IRWD Stock News - GuruFocus
Ironwood (IRWD) Reports Q1 Revenue Shortfall, Ending Quarter with Increased Cash Reserves | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq
Ironwood Pharmaceuticals Q1 2025 Earnings: EPS of -$0.23 Misses Estimate, Revenue Falls Short at $41.14 Million - GuruFocus
Ironwood Pharmaceuticals Reports First Quarter 2025 Results | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Ironwood Pharmaceuticals Reports First Quarter 2025 Results - itemonline.com
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for - Yahoo
Ironwood Pharmaceuticals to Participate in The Citizens Life Sci - GuruFocus
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. - GuruFocus
Ironwood Pharmaceuticals (IRWD) Boosts Earnings Outlook for 2025 - GuruFocus
Ironwood Pharmaceuticals (IRWD) Boosts FY25 EBITDA Forecast Amid Strong Demand | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals hikes adjusted EBITDA guidance to greater than $105M, shares rise - MSN
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - ADVFN
Ironwood Pharmaceuticals Reiterates Full-Year 2025 Guidance and Raises Adjusted EBITDA - TradingView
Ironwood Pharmaceuticals to Present Real-World Data at Digestive - GuruFocus
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support - itemonline.com
Ironwood looks for strategic options after regulatory hurdle for lead drug - MSN
Ironwood Pharmaceuticals to Explore Strategic Alternatives to Maximize Value for Stockholders - marketscreener.com
Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? - MSN
Ironwood Shares Tank on Regulatory Update for Apraglutide - MSN
Ironwood Pharmaceuticals (IRWD) Faces Setback After FDA Request - GuruFocus
Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges A - GuruFocus
Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges Amid FDA Trial Delay | IRWD Stock News - GuruFocus
Ironwood downgraded at Jefferies on apraglutide-related challenges - MSN
Jefferies Downgrades Ironwood Pharmaceuticals (IRWD) - MSN
Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) - MSN
Ironwood downgraded at Jefferies on apraglutide-related challenges (IRWD:NASDAQ) - Seeking Alpha
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7 - marketscreener.com
Jefferies Downgrades Ironwood Pharmaceuticals to Hold From Buy, Adjusts Price Target to $0.70 From $8 - marketscreener.com
Ironwood crashes down as FDA seeks new phase 3 trial - Pharmaphorum
Ironwood (IRWD) Shares Downgraded by Jefferies Following FDA Set - GuruFocus
Ironwood's Strategy Shake-Up Raises Eyebrows As Shares Tumble - Finimize
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide | IRWD Stock News - GuruFocus
Ironwood (IRWD) Plummets After Downgrade and FDA Trial Delay | I - GuruFocus
Ironwood To Consider All Options With Apraglutide Setback In SBS - insights.citeline.com
Ironwood requires new trial for SBS drug approval By Investing.com - Investing.com South Africa
Top Midday Decliners - MarketScreener
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ironwood Pharmaceuticals Inc Stock (IRWD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Silver Ronald | Principal Accounting Officer |
Feb 10 '25 |
Sale |
1.76 |
12,048 |
21,204 |
279,655 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 10 '25 |
Sale |
1.76 |
41,269 |
72,633 |
554,007 |
| John Minardo | Chief Legal Officer |
Feb 10 '25 |
Sale |
1.76 |
38,938 |
68,531 |
408,132 |
| Martini Gregory S. | Chief Financial Officer |
Feb 10 '25 |
Sale |
1.76 |
12,052 |
21,212 |
183,810 |
0.82%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):